Roche in deal with moksha8 for Mexico

Brazil-based moksha8 Inc says that it has expanded its strategic partnership with Swiss drug major Roche to commercialize an additional  portfolio of products in Mexico currently generating sales of $140.0  million. It will commercialize products in three therapeutic areas,  central nervous system disease, anti-infectives and inflammation. The  product portfolio consists of well-known brands including Rivotril  (clonazepam), Rocephin (cephtriaxone) and Bactrim (co-trimoxazole).

"moksha8 has established a broad footprint in Latin America with leading  products that are cornerstones of medical care," commented Simba Gill,  chief executive of moksha8, who founded the company in December 2006  with the Texas Pacific Group. "We look forward to continuing our strong  relationship with Roche and driving value from this important portfolio  of products. We are now firmly positioned as the leading partner of  choice for pharmaceutical and biotechnology companies looking to  generate value across Latin America," he added.

In just over a year, moksha8 says it has grown its commercial  organization to over 200 employees in Brazil and Mexico and a portfolio  of products with sales of $200.0 million. The company claims to be is  uniquely positioned as the leading specialty pharmaceutical firm in  Latin America with a strong presence in CNS, anti-infectives and  inflammation.